JUN 14, 2017 04:13 PM PDT

Identifying A Rare Autoimmune Disease at the Cellular Level

WRITTEN BY: Kara Marker

Diagnostic tests for a rare autoimmune disease called anti-phospholipid antibody syndrome (APS) are unreliable, and treatments are not sustainable long-term. However, a new discovery of the disease’s causation from the University of Geneva might alter solutions for both of these problems.

 Anti-phospholipid antibody syndrome occurs when the immune system attacks normal proteins in the blood.

APS is characterized by autoantibodies in the blood plasma that target anticoagulant proteins, leading to excessive blood clotting. Binding of these autoantibodies can occur in the blood vessels and in the placenta, with dangerous consequences such as venous thromboses, strokes, and miscarriages. APS is rare, affecting less than one percent of the population, but this condition often occurs simultaneously with lupus or rheumatoid arthritis.

Current diagnostic approaches for APS require the expertise of a hematologist, an extensive review of a patient’s medical history, and blood tests scanning for three antibodies that indicate APS: anticardiolipin, beta-2 glycoprotein I, lupus anticoagulant. However, variability, specificity, and sensitivity of these tests are not always dependable.

Treatment options for APS almost exclusively involve oral anticoagulants, but extended use raises risk of adverse side effects, especially for pregnant women.

"The current diagnostic tests use the entire protein, which reduces its specificity and leads to standardization issues,” explained Karim Brandt, a researcher from the study. “Consequently, two tests are required at an interval of 12 weeks after a thrombotic episode or following one or more miscarriages. Our new test specifically targets this pathogenic antibody, with rapid and more accurate results."

The new diagnostic approach is to be devised based upon the discovery of the precise location of anti-phospholipid antibody binding. Identifying the exact location of binding allowed scientists to study in detail how the binding occurs and its specific effects on blood clotting. They found that binding triggers the release of pro-inflammatory and pro-thrombotic factors that are the basis of the condition’s dangerous consequences. 

"Our breakthrough could also give rise to a targeted treatment that would neutralize specific pathogenic antibodies, reducing not just their actions but also the side effects associated with the current treatment,” Brandt explained. “It would involve injecting the protein motif we have identified into a patient's circulatory system so that it explicitly binds itself to the pathogenic antibody and prevents it from causing harm."

The present study was published in the journal Haematologica.

Sources: National Heart, Lung, and Blood Institute, University of Geneva

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 05, 2018
Immunology
DEC 05, 2018
Combo-Kick to Battle Lymphoma
Combination immunotherapy has provided remission for patients suffering from Hodgkin's Lymphoma...
DEC 18, 2018
Cancer
DEC 18, 2018
A new spray that can stop skin cancer recurrence and metastasis
Cancer recurrence and metastasis are the leading causes of death in cancer patients; this is why researchers at UCLA developed something that could help in stopping recurrence or metastasis i...
DEC 19, 2018
Immunology
DEC 19, 2018
Breast Cancer - Immunotherapy's Nemesis
Researchers find that breast cancer can evade immunotherapy...
FEB 04, 2019
Immunology
FEB 04, 2019
Heating Up on the Flu
Climate change may affect the future of vaccinations and nutrition....
FEB 16, 2019
Health & Medicine
FEB 16, 2019
The Role of the Gut-Lung Axis in the Development of Tuberculosis
Observations of the human microbiota date back as far as the 1680s when Antonie van Leeuwenhoek noted significant differences in the types of bacteria from...
FEB 13, 2019
Immunology
FEB 13, 2019
Dengue Meet Immune System
A physical interaction between two types of immune cells that plays an essential role in the early fight against dengue virus infection has been observed for the first time....
Loading Comments...